11-5-5　ⓔ文献

  1. Khanna S, Shin A, et al: Management of Clostridium difficile infection in inflammatory Bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol, 2017; 15: 166–174.

  2. Eaden JA, Abrams KR, et al: The risk of colorectal cancer in ulcerative colitis: a meta–analysis. Gut, 2001; 48: 526–535.

  3. Laine L, Kaltenbach T, et al: SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterol, 2015; 148: 639–651.

  4. Kakuta Y, Naito T, et al: NUDT15 R139C causes thiopurine–induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J, 2016; 16: 280–285.

  5. Rutgeerts P, Sandborn WJ, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2005; 353: 2462–2476.

  6. Reinisch W, Sandborn WJ, et al: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 2011; 60: 780–787.

  7. Sandborn, WJ, Feagan BG, et al: Subcutaneous golimumab induces clinical response and remission in patients with moderate–to–severe ulcerative colitis. Gastroenterol, 2014; 146: 85–95.

  8. Ogata H, Matsui T, et al: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut, 2006; 55: 1255–1262.

  9. Lichtiger S, Present DH, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 1994; 330: 1841–1845.

  10. Feagan BG, Rutgeerts P, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013; 369: 699–710.

  11. Sandborn WJ, Su C, et al: Tofacitinib as induction and maintenance therapy for Ulcerative colitis. N Engl J Med, 2017; 376: 1723–1736.

  12. Sakuraba A, Motoya S, et al: An open–label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol, 2009; 104: 2990–2995.